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Background: This study assessed how the food industry applies the knowledge and evidence gained from
synbiotics, probiotics or prebiotics research in infants, on the general paediatric population. This study also
explored: what happens after the clinical trials using infant formula are completed, data is published or remains
unpublished; the effectiveness and type of medium the formula manufacturers use to educate consumers on
probiotic, prebiotic or synbiotic infant formula.
Findings: This was a descriptive study (a survey) that used a structured questionnaire. All listed companies that
manufacture and / or market food products with added probiotics, prebiotics or synbiotics for infants were
identified and invited to participate. People responsible for research and development were invited to participate in
the survey. A letter of invitation was sent to selected participants and if they expressed willingness to take part in
the study, a questionnaire with a written consent form was sent. Descriptive statistics and associations between
categorical variables were to be tested using a Chi-square test, a p < 0.05 was statistically significant.
A total of 25 major infant formulas, baby food manufacturers were identified, invited to participate in the survey. No
company was willing to participate in the survey for different reasons: failure to take any action 5 (20%), decision to
participate indefinitely delayed 2 (8%), sensitivity of requested information 3 (12%), company does not conduct
clinical trials 1 (4%), company declined without further information 4 (16%), erroneous contact information 6 (24%),
refusal by receptionists to forward telephone calls to appropriate staff 3 (12%), language barrier 3 (12%), company
no longer agrees to market research 1 (4%).
Conclusion: Due to a poor response rate in this study, no conclusion could be drawn on how the food industry
applies evidence gained through probiotics, prebiotics or synbiotics research on infants for the benefit of the
general paediatric population. More information and greater transparency is needed from the infant formula
manufacturers on how they apply the evidence gained from the research on probiotics, prebiotics and synbiotics
on infants.
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Scientific evidence from numerous studies in the last
25 years confirms that breastfeeding is the optimal way
to feed infants, since breast milk contains all the essential
nutrients to meet babies’ needs, as well as antibodies that
fight off infection [1-4]. The World Health Organisation
(WHO) estimates, that if women breastfed their infants,* Correspondence: nkmugambi@hotmail.com
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unless otherwise stated.up to 1.5 million infant deaths or 13% of deaths in chil-
dren under 5 years old could be prevented annually [5].
Despite the benefits of breastfeeding, more women are
choosing formula feeding, either exclusively or giving
mixed feeds (both formula and partial breastfeeding).
Globally, this has resulted in sales of infant formula
skyrocketing creating stiff competition among infant
formula companies to manufacture new and innovative
products [5].
A factor driving research and innovation in the infant
food industry is the need to understand the compositionral Ltd. This is an Open Access article distributed under the terms of the Creative
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scientists continuously conduct research to identify how
infant formula can be adapted to more closely resemble
the composition and function of human milk. This has
resulted in different components being added to infant
formula such as docosahexaenoic acid (DHA), arachi-
donic acid, synbiotics, probiotics or prebiotics [6-9].
Probiotics, prebiotics and synbiotics
Probiotics are defined as “live microorganisms” which
when administered in adequate amounts may confer a
health benefit to the host. [9-11] The main probiotics used
worldwide are Lactobacillus and Bifidobacteria which are
found in the gastrointestinal (GI) microflora [11,12]. For-
mula companies have been adding probiotics to infant
formula [11-16].
Prebiotics are non- digestible food ingredients that
may benefit the host by selectively stimulating the growth
and/or activity of one or a limited number of bacteria in
the colon and improving the host’s health [9,10,17,18].
The most widely studied prebiotics are inulin and fructo-
oligosaccharide (FOS) which are added to different foods
as fat and sugar replacements to improve texture or for
their functional benefits [9,10]. The latter is why formula
companies now add prebiotics to infant formula. Adding
prebiotics to formula stimulates the growth of only benefi-
cial bacteria in the gastrointestinal tract to levels found in
breastfed infants [17-19].
When probiotics and prebiotics are administered simul-
taneously, the combination is termed Synbiotics [9,10,19].
A new trend in the infant food industry is the addition of
synbiotics to infant formula.
How strong is the evidence for adding probiotics,
prebiotics and synbiotics to infant formula?
There is evidence that a healthy GI microflora in infants
is necessary to achieve optimal health and growth [20].
For infants who are not breastfed, there is a rational to
adapt infant formulas to promote an intestinal microbiota
resembling that of breastfed infants, which has greater
concentration of bifidobacteria, fewer potentially patho-
genic bacteria than formula fed infants. This is achieved
by adding probiotics, prebiotics or synbiotics to infant for-
mula for full term and preterm infants [11]. Adding these
ingredients to infant formula changes the intestinal micro-
biota of infants [19,21,22].
Systematic reviews of randomized clinical trials offer
the highest level of evidence for information on the effect-
iveness of an intervention [23-25]. Systematic reviews on
full term infants given probiotics show certain strains
of probiotics improve stool consistency and frequency
(Lactobacillus GG) [26], other strains increase average
formula intake (L. reuteri, B. lactis) [22], and support
normal growth (B. lactis, B. longum BL999, L. rhamnosusLPR, Lactobacillus GG, L. reuteri ATCC 55730) [26]. For
preterm infants, administration of probiotics results in re-
duced risk of Necrotising Enterocolitis (from combina-
tions of Lactobacillus bifidus, streptococcus thermophillus,
and bifidobactrium infantis) and mortality (L acidophilus
and B infantis) [27].
Prebiotics have a good safety record at levels found in
existing food components. Flatulence or abdominal bloat-
ing are reported at doses greater than 20 g/day. Abdom-
inal cramps or diarrhoea are reported at doses greater
than 50 g/day [19]. Adding prebiotics to formula stimu-
lates the growth of only beneficial bacteria in the gastro-
intestinal tract to levels found in breastfed infants and
improves intestinal architecture which reduces intestinal
permeability [12,19,28-31].Communication of best evidence to the consumer
The environment for communicating health and nutri-
tion information has changed in recent years due to an
increase of television, radio channels, internet usage, and
new media such as social networking sites, podcasts and
webinars [32]. To communicate with the consumers, the
food industry uses multiple channels to promote and sell
their products with a goal of achieving profitable growth.
The food industry uses subtle messages of better nutri-
tion as part of their promotional activities [33]. In the
context of probiotics, prebiotics containing food prod-
ucts, the consumer may not understand the meaning or
importance of scientific terms such as probiotics, Lacto-
bacillus, fructooligosaccharide or inulin. Thus, there is a
great need for clear information in a language that the
consumer can understand.Rationale for research
To our knowledge, there are no studies that have as-
sessed how the food industry applies the knowledge and
evidence gained from research on probiotics, prebiotics
or synbiotics on the general paediatric population. This
study attempted to explore what happens after research
trials using infant formula have been conducted and the
data is published or remains unpublished. Based on the
new scientific evidence, do the companies routinely de-
velop and market a new probiotic, prebiotic or synbiotic
containing infant formula, or improve on one that is
already sold on the market?
Probiotic infant formulas have been sold in Europe
and Asia in the last 15 years but are not used widely in
North America [34]. A physical check of several retail
outlets in the Western Cape, South Africa, yielded few
brands (sometimes only two) of probiotic containing in-
fant formula. Yet several companies (in collaboration with
academic institutions) have conducted research projects
using probiotics and prebiotics on infants in Southern
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differences between the study formula and the retailed
product. It is not clear how the manufacturers of pro-
biotic, prebiotic or synbiotic containing infant formula
educate the consumers on their products. This study
set out to answer product specific questions on genera
of probiotics used, product viability at end of shelf
life, differences between study and retailed product.
As well as explore the effectiveness and type of me-
dium the infant formula manufacturers use to educate
the consumers on probiotic, prebiotic or synbiotic in-
fant formula.
Safety issues are also an area of concern. The two
probiotic infant formula brands available in the Western
Cape, South Africa retail outlets state that using water
with temperatures above 40°C (degrees centigrade) will
compromise the natural cultures. This contradicts the
WHO “Guidelines for safe preparation, storage and
handling of powdered infant formula” which recom-
mends that water with a minimum temperature of 70°C
should be used to minimize the risk of potentially
deadly infections caused by Enterobacter Sakazakii,
bacteria that has been found in infant formula [37].
In addition there is a lack of published evidence on
clinical benefits from long term use of probiotic con-
taining infant formula [26,38]. This study tried to ex-
plore how the infant formula companies address the
contradiction to WHO guidelines on formula preparation
and safety issues of long term usage of probiotic infant
formula.
Research question
Does the food industry apply the evidence gained through
probiotics, prebiotics and synbiotics research on infants
for the benefit of the general paediatric population?
Research aim
To investigate how the infant food industry applies evi-
dence gained through probiotics, prebiotics and synbio-
tics research on infants.
Objectives
The objectives of this study were to determine the
following:
Application of evidence:
1. If new research evidence resulted in new infant
formula products been developed,
2. If there were any differences in study and retailed
infant formula,
3. The frequency of conducting research using
probiotics, prebiotics or synbiotics containing infant
formula.Publication of results:
4. If the infant formula companies had intentionally
NOT published study results that were viewed as
negative or having no clinical benefit to infants?
5. If study results perceived to be negative, were
withheld and was new research conducted to
confirm the results?
Medium for consumer education:
6. The type and effectiveness of medium used to
educate the consumer,
7. The presence of bias in promoting formula feeding
more than breastfeeding.
Compliance to WHO guidelines:
8. How formula companies complied with WHO
guidelines on formula preparation with a focus on
high water temperature and its effects on
probiotics, synbiotics containing infant formula?
Safety of long term use of probiotic or synbiotic
containing infant formula,
9. How companies addressed safety, since there is a
lack of published evidence on the clinical benefits of
long term consumption of probiotic containing
formula (longer than 1 year).
Product viability,
10. If the probiotic, synbiotic containing infant formula
remain viable throughout storage or are there
substantial changes in the number of colony
forming units at the end of shelf life?
How companies keep abreast of the latest research on
probiotics, prebiotics and synbiotics in infant formula
and weaning foods?
11. If the formula companies had staff designated to
keep track of research or was it on “ad hoc” basis?
Methodology
Study design
This was a descriptive study (a survey) employing the use
of a structured questionnaire developed by the researcher.
Company selection
Companies that manufacture and/or market food prod-
ucts with added probiotics, prebiotics or both (synbiotics)
for infants and children were identified through several
Table 1 List of 25 baby food companies and infant
formula manufacturers invited to participate in survey
Company name Company name
Abbott Laboratories/Abbot
Nutrition
Milupa
Aspen Phamarcare Morinaga Milk industry Co. Ltd
Beech-nut nutrition corporation Nestle (South Africa and Switzerland)
Danone baby and medical
nutrition BV
Organix brands
Earth's Best (Hain Celestian Group) Pfizer Inc (SA) and Pfizer Head office
FrieslandCampina (Netherlands) Raptakos Brett & Co. Ltd.
Gerber products company SMA Nutrition (Ireland and UK)
Hangzhou Beingmate Group
Co Ltd.
Synutra International
HiPP GmbH & Co Vertrieb KG Tiger brands
JH J Heinz Wakodo Co. Ltd
Kewpie Wockhardt Limited
Mead Johnson Hero AG
Meiji Dairies
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and DATAMONITOR360. In addition, company websites
were visited to acquire the contact information of indi-
vidual companies. The person/people responsible for re-
search and development were invited to participate in the
survey. Study participants included clinical research man-
agers and individual researchers in the infant food com-
panies. Worldwide, the numbers of infant food companies
(especially infant formula manufactures) are few. There-
fore all listed companies were invited to participate in the
study. The number of study participants per company was
one or two.
Data collection and processing
A letter of invitation was sent to selected participants,
inviting them to take part in the study. The letter of invi-
tation explained all aspects of the study, and if they
expressed willingness to take part in the study, a ques-
tionnaire with a written consent form was sent via post,
email or fax. If the questionnaire was posted, a stamped
envelope was included for returning the completed ques-
tionnaire to the researcher. A maximum of four reminders
were given to the participants to complete the question-
naire. The participants were free to withdraw from the
study at any time without any consequence.
Due to the expected small sample size, maintaining
anonymity of study participants with the corresponding
company name was difficult. Therefore, data process-
ing was done according to product and company name.
However, during report writing, all identifying details
(name of study participant, product and company name)
were excluded. Only the researcher and statistician had
access to the data.
Questionnaire description
A questionnaire was designed for this study based on
relevant published information. The questionnaire focused
on product specific questions, research based questions,
education of consumers and safety issues. It was validated
for content by sending it to experts in the field of probio-
tics, prebiotics and infant nutrition, who were able to
judge if the questionnaire met the objectives of the study.
These experts did not partake in the study nor were they
associated with the infant food industry.
Data analysis
Researchers planned to enter the collected data into SPSS
(Statistical Program for Social Sciences) for analysis. The
data was to be analysed using descriptive statistics and as-
sociations between categorical variables, be tested using a
Chi-square test. A p < 0.05 was considered statistically sig-
nificant. A statistician was consulted at every step of the
study process.Ethics approval
Ethics approval to conduct this study was given by the
Human Research Ethics Committee at the University of
Stellenbosch, Faculty of Medicine and Health Sciences,
reference number N11/07/203.
Findings
A total of 25 major infant formula and baby food manu-
facturers were identified from around the world and in-
vited to participate in the survey (Table 1). A total of 5
(20%) companies initially agreed to participate but took
no action by not signing the informed consent form and
completing the questionnaire. The decision to parti-
cipate in the study was delayed indefinitely for 2 (8%)
companies since their head of department was too busy
to make a final decision. Sensitivity that the requested
information would give the competition an advantage
was cited by 3 (12%) companies for not participating in
the study, while 1 (4%) company stated they manufac-
ture baby food and distribute it for retail without con-
ducting any clinical trials. A total of 4 (16%) companies
declined to participate without giving any further infor-
mation. Erroneous contact information given on com-
pany websites hindered any contacted being made with
6 (24%) companies. Company representatives from 3
(12%) companies refused to forward telephone calls from
the researchers to the appropriate department and staff.
Three (12%) companies cited language barrier (Mandarin,
German, Dutch) as a reason for not participating in the
study, despite offers to professionally translate the study
documents into a language of their choice. One (4%) com-
pany stated that it was overwhelmed with people making
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tured and “market research was no-longer a priority”
(Table 2). In the end no company was willing to partici-
pate in the survey.
Discussion
To our knowledge, this was the first study to explore
how the food industry applies evidence gained through
research on probiotics, prebiotics and synbiotics on in-
fants for the benefit of the general population. As a direct
result of the poor response rate in this survey, several
study objectives and key questions remain unanswered.
These are discussed below.
Application of evidence
Despite more than 30 years of research on probiotics,
prebiotics or synbiotics on infants and children, any dif-
ferences between studied and retailed infant formula
such as the strains of probiotic bacteria used could not
be established. It remains unknown if new evidence from
clinical trials led to the improvement of existing formula,
development of new infant formula or weaning foods
containing probiotics or synbiotics.
Publication of results (Publication bias)
Publication bias is defined as “the tendency for investiga-
tors, journal editors and reviewers to submit or accept a
manuscript for publication based on the directions or
strength of the study findings [39]. Publication bias canTable 2 Reasons for not participating in survey
Reason(s) for not participating in survey N =25
Number of
companies n (%)
No Action taken by company after agreeing to
participate in survey
5 (20%)
Head of department too busy to make decision 2 (8%)
Requested information too sensitive - may give
competition an advantage
3 (12%)
Company does not conduct clinical trials, just
manufacture infant food, distribute it for retail
1 (4%)
No reason given for declining to participate in survey 4 (16%)
Researchers unable to make contact with company
through use of internet (emails, “contact us” features
in company websites), telephone, fax or post office.
6 (24%)
Company receptionist/contact person refused to
forward call/put researchers in touch with
appropriate person to answer questions
3 (12%)
Quote: “Too many people conducting market
research on company, company has other priorities
than answering market research questions.”
1 (4%)
Language barrier – “prefer questionnaire in local
dialect” such as Mandarin, Dutch, German.
3 (12%)
Note: Several companies gave more than one reason for not participating
in survey.have far reaching consequences on the public. For ex-
ample, if an intervention that is not effective is falsely
considered effective and administered to patients, an ef-
fective treatment that is available is withheld. Not pub-
lishing results from research where the intervention is
discovered to be harmful; may indirectly harm study par-
ticipants taking part in future research. This is because
other investigators will (unknowingly) repeat the same
research, testing the harmful intervention, causing suf-
fering on a different group of people [39]. This study
was not able to establish if companies engaged in re-
search had intentionally NOT published study results
that were viewed as negative or not having any clinical
benefits to infants and children. Whether companies con-
ducted new research to confirm results that may have
been perceived as negative could not be established.
Medium for consumer education
The type and effectiveness of medium used to educate
the consumer on probiotics, prebiotics or synbiotics con-
taining formula or baby foods could not be established.
The numerous techniques used by the formula and baby
food industry to increase awareness of their products are
beyond the scope of this study and are described else-
where. Only one education and promotion technique is
illustrated below.
Internet
The internet is an important source of health informa-
tion for parents [40-42]. Company websites offer advice
on infant feeding, child rearing and health care issues.
Some websites have useful product information, most
websites use information on breastfeeding to jump to
the second best option; formula feeding [3].
Most websites of formula manufacturers have prod-
uct specific content concerning infant formula brands.
Websites present images of branded packs linked with
information about specific infant formula. These web-
site links are accessible to the public, health and medical
professionals. Research has shown consumers (mothers)
get confused with formula advertising [40]. In situations
where infant formula and follow-on formula share brand
identities, consumers recall advertising and messages for
follow-on formula and think it also applies to infant for-
mula. As a result, information and promotional messages
designed around follow-on formula are transferred to in-
fant formula products. This type of confusion has far
reaching implications [40].
Navigating the websites of the 25 companies invited to
participate in this study, in addition to the product spe-
cific content in the websites, only eight companies had
brief descriptions of probiotics or prebiotics, five com-
panies had health claims on probiotics and one company
had a health claim on prebiotics. There was no mention
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products. In addition, the information on probiotics and
prebiotics was difficult to obtain from the websites and
could be inaccessible to consumers without advanced
computer skills, tertiary education or sufficient know-
ledge on what to look for.
Compliance to WHO guidelines
The position of formula companies on how they comply
with WHO guidelines on water temperature during for-
mula preparation could not be established. WHO rec-
ommends diluting the powdered formula in water at a
temperature of at least 70°C to inactivate cronobacter
spp. (Enterobacter sakazakii) [37]. South Africa’s “Regu-
lations Relating to Foodstuffs for Infants and Young
Children, Government Gazette number 35941” state that
labels for any infant formula, follow-up formula must
“provide instructions for appropriate use according to
the latest FAO/WHO guidelines.” The gazette requires
the labels to state that infant formula is not always ster-
ile and may contain harmful microorganisms, emphasiz-
ing appropriate preparation [43]. Yet the labels of infant
formula found in retail stores of Western Cape, South
Africa do not recommend using water above 40°C.
The European Society of Pediatric Gastroenterology,
Hepatology and Nutrition (ESPGHAN) committee on nu-
trition and French Food Safety Agency (AFSSA) disagree
with WHO guidelines and state that heating water to tem-
peratures greater than 70°C is not necessary and maybe
harmful to the nutritional quality of formula. Using hot
water (greater than 70°C) may lead to formation of curds,
risk of severe burns and the loss of 10 to 25% of some nu-
trients: Thiamine, Vitamins B1, B6, B12, Folic acid, and
Vitamin C [44,45]. The effect of water temperature on
Cronobacter spp. (Enterobacter sakazakii) is striking. At
37 to 39°C, there is optimal growth, at 5.5 to 8°C there is
minimal growth. At room temperature, Cronobacter spp.
has the potential for rapid growth [44,45]. It is worth not-
ing the rate of contamination with Cronobacter spp. has
decreased over the years from 14% in 1980s to 2.4% in
mid 2000s [44-46].
Safety of long term use of probiotics or synbiotics
containing formula
The way companies address the question on safety of
long term consumption of probiotics, synbiotics of in-
fant formula could not be established. Safety of long
term use is an important issue since majority of consu-
mers of probiotics, synbiotics containing formula and
baby foods use these products for more than a year. Ac-
cording to ESPGHAN committee on nutrition, there is a
lack of published evidence on the clinical benefits and
safety from long term consumption of probiotic contain-
ing formula [26,38]. How the formula and baby foodcompanies educate the consumer on this issue is yet to
be determined or observed.
Product viability
Whether bacteria in retailed probiotics or synbiotics
containing infant formula remain viable throughout shelf
life was not established in this study. There are few re-
ports on the stability of probiotics in powdered formula
for infants and toddlers [47]. Several studies have con-
ducted long term stability tests on bifidobacteria in
powdered formula and results show the viability of live
bacteria (such as bifidobacteria) decreased with length
of time in storage and with increase in temperature
[47,48]. Consumers usually store powdered formula at
room temperature. However, the formula may be exposed
to high temperatures during transportation, during hot
seasons or, in countries with hot weather conditions. If
there is a large reduction in viable cell counts of probiotic
bacteria, the commercial use of the formula is lost and the
consumer does not benefit from the expected probiotic ef-
fects [47]. The change in stability at various storage tem-
peratures should be made clear by formula manufacturers.
How companies keep abreast of the latest research on
probiotics, prebiotics and synbiotics in infant formula and
weaning foods
How companies keep abreast of the latest research on
probiotics, prebiotics and synbiotics in infants could not
be established. This study tried to find out if there are
any formal mechanisms in place to ensure that emplo-
yees or researchers keep abreast of the latest research.
The formula and baby food industry needs to be more
transparent on this issue.
Limitations
Sampling frame
Only online electronic databases were used to identify
the companies around the world that manufacture infant
food products with probiotics, prebiotics or synbiotics.
Small regional companies that were not listed in the elec-
tronic databases were missed and subsequently not invited
to participate in the study. Different methods could have
been used to identify small regional companies.
Selection bias (under-coverage bias)
Efforts were concentrated on inviting people responsible
for research and development such as clinical research
managers and individual researchers. Other staff such as
product managers could have been invited to participate
in the study.
Survey participation rates, non-response bias
Survey participation rates were nil. Many company staffs
were cautious after the initial contact and invitation to
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were unwilling to participate in the survey. During tele-
phone conversations with the some company employees,
the researchers were perceived to be in collaboration
with the competition.
Conclusion
Due to a poor response rate, no conclusion could be
drawn on how the food industry applies evidence gained
through probiotics, prebiotics or synbiotics research on
infants and children for the benefit of the general paedi-
atric population. More information with greater trans-
parency is needed from the infant formula and baby
food companies on how they apply the evidence gained
from the extensive research conducted using probiotics,
prebiotics and synbiotics on infants and children.
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